Durysta

DURYSTA™ is an alternative treatment to topical drops or laser surgery for glaucoma . It is a prescription medicine to reduce intraocular eye pressure in patients with open-angle glaucoma or ocular hypertension (high eye pressure). DURYSTA™ is a sustained released biodegradable implant containing 10 mcg of bimatoprost.

DURYSTA™ is the first and only FDA-approved biodegradable, intracameral implant providing sustained reduction of intraocular pressure.

DURYSTA™ Implant Treatment for Glaucoma at FSN Eye Center

If you are interested in the DURYSTA™ implant treatment for glaucoma, call FSN Eye Center at (815) 932-2020  to request an appointment. For your convenience, you may also request an appointment  online.

DURYSTA™ FAQs

The DURYSTA™ implant is about 0.2 mm in diameter and 1 mm in length, smaller than the “L” in LIBERTY on a dime. Because the implant is biodegradable, it doesn’t remain in the eye permanently.

DURYSTA™ is a dissolvable implant placed directly inside your eye by your eye doctor. DURYSTA™ is a drug delivery system for your eye. As DURYSTA™ dissolves, it automatically releases medicine to help reduce high pressure inside your eye.

One DURYSTA™ implant lasts for several months. In 2 clinical studies for DURYSTA™, eye pressure was reduced for 15 weeks.

DURYSTA™ is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

The pressure inside your eye is called intraocular pressure (IOP). When IOP is elevated, it’s a major risk factor for vision loss associated with glaucoma over time. The higher the level of IOP, the greater the chance of optic nerve damage and vision loss.

Open-angle glaucoma is the most common type of glaucoma. The drainage angle of the eye is open, but working less efficiently, usually due to age. As a result, eye pressure builds up slowly, causing a gradual loss of side vision.

DURYSTA™ is a first-in-class, biodegradable, intracameral implant for IOP control with 24/7 drug delivery for several months.

 

DURYSTA™ is not intended for patients with the following conditions:

  • Active or suspected ocular or periocular infections
  • Corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy)
  • Prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK])
  • Absent or ruptured posterior lens capsule due to the risk of implant migration into the posterior segment
  • Hypersensitivity to bimatoprost or any other components of the product

 

DURYSTA™ should be limited to a single implant per eye without retreatment.

The most common side effect reported by patients using DURYSTA™ was eye redness. Other common side effects reported were feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache. See full Prescribing Information for complete safety information.

 

If your eye becomes red, sensitive to light, painful, or if your vision changes, you should seek immediate care from your ophthalmologist. It is important to follow your eye doctor’s instructions closely. After you receive DURYSTA™, you must be monitored by your eye doctor.

Ask your eye doctor if you’re eligible to pay as little as $20 for a DURYSTA™ implant.* Learn more about Allergan’s Savings Program here.

*$1000 maximum benefit per eye; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). Other limitations may apply.